SESSION 1. DIABETES & CARDIORENAL DISEASE
Chair: Paul Kalra, Consultant Cardiologist (Portsmouth Hospitals NHS Trust)

09.30 Which drug for which patient?
David Strain, Clinical Senior Lecturer (University of Exeter) and Honorary Consultant (Royal Devon and Exeter Hospital)

09.55 Discussion

10.00 Understanding the pathogenesis of vascular disease in diabetes, hypertension and obesity – does it influence treatment?
Anthony Heagerty, Professor of Medicine and Head of Division of Cardiovascular Sciences (University of Manchester)

10.25 Discussion

10.30 Lipid management in vascular disease – when to consider options beyond statins
Dermot Neely, Consultant in Clinical Biochemistry and Metabolic Medicine (Newcastle upon Tyne Hospitals NHS Trust)

10.55 Discussion

11.00 Coffee break

SESSION 2. CARDIORENAL CLINICAL UPDATES
Chair: Catherine Wall, Consultant Nephrologist (Tallaght University Hospital, Dublin, Ireland)

11.30 The British Heart Valve Society Lecture
Advances in percutaneous treatment of valvular disease in patients with cardiorenal disease
Phil MacCarthy, Professor of Interventional Cardiology (King’s College London) and Consultant Cardiologist (King’s College Hospital, London)

11.50 Discussion

11.55 The British and Irish Hypertension Society Lecture
Blood pressure targets in patients with cardiorenal disease. What do the guidelines say?
Una Martin, Professor of Clinical Pharmacology (University of Birmingham)

12.15 Discussion

12.20 British Heart Foundation Lecture
Alternative pathways to immunosuppression
Federica Marelli-Berg, British Heart Foundation Chair of Cardiovascular Immunology (William Harvey Research Institute, Barts and The London School of Medicine and Dentistry)

12.40 Discussion

12.45 Lunch break

SESSION 3. CLINICAL TRIAL UPDATE
Chairs: Abhishek Joshi, President of the BJCA and Matthew Graham-Browne, Chair of the UK and Ireland RA Nephrology SpR Club

13.55 Cardiology trials reviewed
Lisa Anderson, Heart Failure Consultant and Head of Clinical Governance and Audit Cardiology Clinical Academic Group (St. George’s University Hospitals NHS Foundation Trust, London)

14.15 Discussion

14.20 Nephrology trial network in the UK – does it work?
Philip Kalra, Professor of Renal Medicine (University of Manchester) and Consultant Nephrologist (Salford Royal NHS Foundation Trust)

14.40 Discussion

SESSION 4. IMPROVING PATIENT CARE – EXAMPLES OF COLLABORATIVE WORKING BETWEEN CARDIOLOGISTS AND NEPHROLOGISTS
Chair: David Lappin, Consultant Nephrologist (Galway University Hospitals, Ireland)

14.45 How to manage deteriorating renal function in patients with heart failure on RAAS blockade
Charles Tomson, Consultant Nephrologist (Freeman Hospital, Newcastle upon Tyne)

15.05 Discussion

15.10 Sudden cardiac death in end stage renal disease
Paul Roberts, Consultant Cardiologist (University Hospital Southampton NHS Trust)

15.30 Discussion

15.35 Tea break

SESSION 5. INTERACTIVE CLINICAL CASES
Chair: David Mulcahy, Consultant Cardiologist (Tallaght University Hospital, Dublin, Ireland)

15.55 Case 1. Hyperkalaemia
Paddy Mark, Clinical Reader and Honorary Consultant Nephrologist (Queen Elizabeth University Hospital, Glasgow)

16.15 Case 2. Anticoagulation and CKD
Charles Ferro, Consultant Nephrologist (University Hospitals, Birmingham)

16.35 Case 3. Iron deficiency
Paul WX Foley, Consultant Cardiologist (Great Western Hospital, Swindon)

16.55 Case 4. Atypical haemolytic uraemic syndrome
Neil Sheerin, Professor of Nephrology (Newcastle University)

17.15 Close

6 CPD credits awarded the Royal College of Physicians
Endorsed by the Renal Association, the Irish Nephrology Society and the British Society for Heart Failure.
Registration fee with lunch and refreshments: £130, £75 concessions (nurses and clinical trainees), £250 commercial organisations